Gadobutrol - CAS 770691-21-9
Catalog number: B0084-463325
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
Molecular Weight:
Certificate of Analysis-Gadobutrol 770691-21-9 B15H1014  
Gadobutrol is a nonionic, paramagnetic contrast agent developed for tissue contrast enhancement in magnetic resonance imaging (MRI). It has a macrocyclic framework and is neutral. It is a water-soluble, highly hydrophilic compound with a partition coefficient between n-butanol and buffer at pH 7.6 of ~ 0.006.
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-463325 1 g $298 In stock
Bulk Inquiry
Publictions citing BOC Sciences Products
  • >> More
≥ 99.5%
Related CAS:
White, odorless amorphous powder
Gadograf; Gadovist; Protovist; ZK 135079; Gd-DO3A-butrol; Gallium 10-(1,3,4-trihydroxybutan-2-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-tricarboxylate; 770691-21-9; AK325914; gallium; 10-(1,3,4-trihydroxybutan-2-yl)-1,4,7,10-tetrazacyclododecane-1,4,7-tricarboxylate; (SA-​8-​1425362’5’)​-[rel-​10-​[(2R,​3S)​-​2-​(hydroxy-​κO)​-​3-​hydroxy-​1-​(hydroxymethyl)​propyl]​-​1,​4,​7,​10-​tetraazacyclododecan​e-​1,​4,​7-​triacetato(3-​)​-​κN1,​κN4,​κN7,​κN10,​κO1,​κO4,​κO7]​-​gadolinium;
Easily soluble in water, slightly soluble in methanol and ethanol, practically insoluble in chloro-form and acetone.
A gadolinium-based MRI contrast agent (GBCA)
Quality Standard:
In-house standard
Melting Point:
>300ºC (dec.)
Canonical SMILES:
1.Gadobutrol: an alternative contrast agent for digital subtraction dacryocystography
M. Priebe, A. Mohr, J. Brossmann, M. Heller, C. Frahm. Eur Radiol (2002) 12:2083–2086
Theoretically, X-ray attenuation of gadolinium compares favorably with that of iodine, as the absorption of Xrays depends on the atomic number to the third power. With an atomic number of 64 and a k-edge of 52 keV, gadolinium has photoelectric characteristics similar to those of iodine (atomic number of 53 and k-edge of 33.2 keV); thus, a higher X-ray absorption can be expected from gadolinium. Gadobutrol has the double gadolinium concentration (1.0 mmol/l or 157.34 mg/ml) of the other gadolinium-based contrast agents, resulting in a high radiodensity which is very similar to that of iodinated contrast medium iopentol with a iodine concentration of 250 mg/ml. Due to the high concentration, the radiodensity of gadobutrol is only approximately 20% lower than the concentration of iopentol (300 mg iodine/ml). This correlates well with our impression that the image contrast of DS-DCG with gadobutrol was only slightly inferior to routine DS-DCG studies performed with iopentol.
2.Safety of contrast-enhanced MR angiography employing gadobutrol 1.0 M as contrast material
Jörn O. Balzer, Christian Loewe, Kirsten Davis. Eur Radiol (2003) 13:2067–2074
In three multicenter studies (body MRA study, peripheral MRA study, safety study) conducted in 27 centers from January to December 2000 a total of 436 patients were recruited for CE MRA employing intravenous injections of the new contrast agent 1.0-M gadobutrol (Gadovist, Schering, Berlin, Germany; Table 1). One patient did not receive the study drug and was excluded; thus, the data of 435 patients was included in order to evaluate the clinical safety of 1.0-M gadobutrol injections. Due to organizational limits, not all participating centers had the opportunity to collect data on all safety parameters during the follow-up period. Adverse events (i.e., all adverse reactions observed by the investigator or reported by the patient during the follow-up period) were evaluated in all patients, laboratory values were available from 124 patients, and vital signs (blood pressure and heart rate after at least 5 min recumbence) as well as 12-lead electrocardiogram (ECG) recordings from 93 patients.
3.Double-dose 1.0-M gadobutrol versus standard-dose 0.5-M gadopentetate dimeglumine in revealing small hypervascular hepatocellular carcinomas
Young Kon Kim, Young Hwan Lee, Chong Soo Kim. Eur Radiol (2008) 18: 70–77
Our study result from matched pairs analysis, in which superior lesion-to-liver contrast was noted by all observers for one lesion with gadopentetate dimeglumine compared with gadobutrol despite the low gadolinium concentration of the gadopentetate dimeglumine, is totally opposite to the theoretical expectation. This is because all the study conditions of the two MRIs, except for the contrast agent and the physiologic aspects were all kept constant to permit a direct comparison. In this study, even though the modified VIBE sequence with mSENSE for inducing increased temporal resolution and the resultant double arterial phases were used, as well as a test-bolus technique, two small HCCs were not clearly demonstrated with either MRI. This could be interpreted to mean that it is still difficult to accurately capture the very short enhancement period of small HCCs with MR technology in our study. In other words, under the circumstance of using the 3D-dynamic MR sequence, the accurate timing to capture the arterial phase imaging might be given much more weight for detecting HCCs than the concerns about what extracellular MR contrast agent is used. However, the potential of a more highly concentrated gadolinium chelate has to be further investigated by additional studies using ultra-fast MR equipment, where a compact bolus is advantageous, or an MR protocol such as 2D-dynamic imaging with longer data acquisition time (≈20 s).
4.Intraindividual, randomized comparison of the macrocyclic contrast agents gadobutrol and gadoterate meglumine in breast magnetic resonance imaging
Eva M. Fallenberg & Diane M. Renz & Bettina Karle & Carsten Schwenke. Eur Radiol (2015) 25:837–849
The aim of our study was to investigate whether gadobutrol and gadoterate meglumine differ not only with regard to peak enhancement, which is expected on the basis of their different T1-relaxivities, but also with regard to the time course of signal enhancement, which might be attributable to differences in electric charge. We, therefore, performed an intraindividual comparison of the signal intensity time courses after gadobutrol and gadoterate meglumine administration in women with different benign and malignant breast lesions.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Products

CAS 464-74-4 Arenobufagin

(CAS: 464-74-4)

Arenobufagin is a bufanolide steroid isolated from the Argentine toad Bufo arenarum. This compound exhibits anticancer chemotherapeutic and anti-angiogenic prop...

N-deacetylated BMS-202

The deacetylated of BMS-202 which is a small-molecule PD-1/PD-L1 interaction inhibitor (IC50= 18 nM).

CAS 69207-52-9 McN3716

(CAS: 69207-52-9)

An inhibitor of carnitine palmitoyltransferase I (CPT-1)


GnRH-I, a small 10 amino acid long peptide (decapeptide) from the hypothalamus, has previously been demonstrated and shown to be biologically active in the immu...

CAS 85375-15-1 SKF 89976A hydrochloride

SKF 89976A hydrochloride
(CAS: 85375-15-1)

SKF 89976A hydrochloride is a potent GABA transporter inhibitor with selectivity for GAT-1 (IC50 = 0.13, 550, 944 and 7210 μM for hGAT-1, rGAT-2, hGAT-3 and hBG...

CAS 11027-63-7 Agnuside

(CAS: 11027-63-7)

Agnuside is an iridoid glycoside found in the herbs of Vitex agnus-castus, a plant native to the Mediterranean region. It is the ester of aucubin and p-hydroxyb...

(CAS: 178946-89-9)

C-DIM12 is a novel synthetic activator of Nurr1. C-DIM12 induces dopaminergic gene expression and protects against 6-hydroxydopamine neurotoxicity in vitro. .

CAS 1340875-03-7 PRMT3 inhibitor 1

PRMT3 inhibitor 1
(CAS: 1340875-03-7)

PRMT3 inhibitor 1 is an allosteric inhibitor of protein arginine methyltransferase 3 (PRMT3; IC50 value of 1.6 μM for inhibition of full length PRMT3 in a radio...

CAS 153381-68-1 7-Epi-docetaxel

(CAS: 153381-68-1)

An isomer of Docetaxel (D494420). Docetaxel injection impurity C.

(CAS: 1414375-50-0)

GSK-1268997 is one of a metabolite of Pazopanib which is a selective multi-targeted receptor tyrosine kinase inhibitor that blocks tumour growth and inhibits an...

CAS 107538-05-6 Dexmecamylamine

(CAS: 107538-05-6)

Dexmecamylamine is a nicotinic channel modulator with antidepressant activity. It demonstrated positive effects in a number of animal models of depression and a...

CAS 41078-02-8 Enprofylline

(CAS: 41078-02-8)

Enprofylline, a xanthine derivative, is a a competitive nonselective phosphodiesterase inhibitor with relatively little activity as a nonselective adenosine rec...

(CAS: 1233948-61-2)

EL102, a HIF1α inhibitor, has been found to have potential effect in restraining polymerisation of tubulin and influencing the stability of microtubule. IC50: 2...

CAS 23651-95-8 Droxidopa

(CAS: 23651-95-8)

Droxidopa(L-DOPS, SM5688) is a synthetic amino acid precursor which acts as a prodrug to the neurotransmitters norepinephrine (noradrenaline) and epinephrine (a...

CAS 600-57-7 11beta-Hydroxyprogesterone

(CAS: 600-57-7)

11beta-Hydroxyprogesterone is a potent inhibitors of 11β-Hydroxysteroid dehydrogenase and can confer mineralocorticoid activity on corticosterone in the rat in ...

(CAS: 749269-77-0)

CHF-5022 is a non-steroidal anti-inflammatory agent. It can selectively inhibit the production of beta-amyloid(1-42) .

CAS 341-69-5 Orphenadrine hydrochloride

Orphenadrine hydrochloride
(CAS: 341-69-5)

A skeletal muscle relaxant used to treat drug-induced parkinsonism and to relieve pain from muscle spasm.

CAS 614-39-1 Procainamide Hydrochloride

Procainamide Hydrochloride
(CAS: 614-39-1)

Procainamide, a derivative of procaine with less CNS action., is an agent indicated for production of local or regional anesthesia and in the treatment of ventr...

CAS 736994-63-1 Cyantraniliprole

(CAS: 736994-63-1)

Cyantraniliprole is an insecticide of the ryanoid class. It has activity against pests such as Diaphorina citri.

(CAS: 1224095-98-0)

This bio-active molecular is a broad-spectrum antibiotic that has potent Gram positive activity and Gram negative coverage. Brilacidin is highly effective in tr...

Chemical Structure

CAS 770691-21-9 Gadobutrol

Quick Inquiry

Verification code

Featured Items